Agenus: Weighing The Clinical Progress Against The Company's Cash
Agenus Inc. is currently viewed as a speculative investment, primarily driven by its BOT/BAL product. Recent developments, including the Phase III BATTMAN trial and a partnership with Zydus, indicate progress in both clinical and commercial aspects. Despite these advancements, the company's conviction rating remains low at 2 out of 5.
- ▪Agenus Inc. is considered a speculative play with a focus on its BOT/BAL product.
- ▪The Phase III BATTMAN trial and new data on HCC suggest clinical progress.
- ▪A recent partnership with Zydus provided $91 million upfront, enhancing manufacturing capacity.
Opening excerpt (first ~120 words) tap to expand
{"@context":"https://schema.org","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https://seekingalpha.com/"},{"@type":"ListItem","position":2,"name":"Stock Ideas","item":"https://seekingalpha.com/stock-ideas"},{"@type":"ListItem","position":3,"name":"Long Ideas","item":"https://seekingalpha.com/stock-ideas/long-ideas"},{"@type":"ListItem","position":4,"name":"Healthcare…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Seeking Alpha.
Discussion
0 commentsMore from Seeking Alpha
